Immunotherapy-Chemo cocktail shows promise for Hard-to-Treat bile duct cancer
NCT ID NCT07668453
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (gemcitabine and nab-paclitaxel) as a first treatment for people with biliary tract cancer that cannot be removed by surgery. The goal is to see if this combo can shrink tumors and improve survival. Thirty participants will all receive the same treatment, and researchers will monitor side effects and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- adebrelimab (immunotherapy) combined with gemcitabine and albumin-bound paclitaxel (chemotherapy)
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with biliary tract cancer that cannot be surgically removed, potentially shrinking tumors and extending survival.
- What could go wrong
- This is a small, early-phase (Phase 2) study with only 30 participants, so results may not apply to all patients. The combination may cause significant side effects, and there is no guarantee it will work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangsu Provincial People's Hospital
RECRUITINGNanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- New drug cocktail aims to outperform standard immunotherapy in bile duct cancer
- Liver cancer registry aims to uncover new biomarkers from thousands of patients
- Triple-Drug cocktail targets Hard-to-Treat biliary cancers